argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-09 07:41 |
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
|
English | 72.5 KB | ||
| 2022-12-13 09:06 |
argenx Appoints Ana Cespedes to Board of Directors
|
English | 18.8 KB | ||
| 2022-12-12 07:45 |
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlig…
|
English | 137.6 KB | ||
| 2022-11-30 08:55 |
argenx Enters Into Agreement To Acquire Priority Review Voucher
|
English | 29.5 KB | ||
| 2022-11-22 07:43 |
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcu…
|
English | 68.2 KB | ||
| 2022-11-07 08:07 |
argenx to Present at Upcoming Investor Conferences
|
English | 23.8 KB | ||
| 2022-10-27 07:44 |
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
|
English | 158.9 KB | ||
| 2022-10-20 07:44 |
argenx to Report Third Quarter 2022 Financial Results and Business Update on Oc…
|
English | 19.3 KB | ||
| 2022-09-21 21:05 | English | 1.1 MB | |||
| 2022-09-21 14:16 |
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medic…
|
English | 157.8 KB | ||
| 2022-09-21 14:16 |
argenx Submits Biologics License Application to U.S. Food and Drug Administrati…
|
English | 73.5 KB | ||
| 2022-09-09 08:04 |
argenx Appoints Camilla Sylvest to Board of Directors
|
English | 18.2 KB | ||
| 2022-08-31 08:06 |
argenx to Present at Wells Fargo Healthcare Conference
|
English | 16.4 KB | ||
| 2022-08-11 13:18 |
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fc…
|
English | 53.0 KB | ||
| 2022-07-28 09:02 |
argenx announces Extraordinary General Meeting of Shareholders on September 8, …
|
English | 21.3 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
